PRRX2 (Paired Related Homeobox 2)

Also, the expression levels of PRRX1, PRRX2 between patients with LVI+ and those with LVI-, with p-values of p<0.0001, p<0.0001 for each. These findings suggest that PRRX1and PRRX2 levels could be used as possible diagnostic indicators for colorectal cancer.

Our findings reveal that PHOX2B positively regulates PHOX2B-AS1 expression and that inhibiting the antisense transcript reduces PHOX2B protein levels. Together, these results provide strong evidence for the existence of a gene antisense to PHOX2B and highlight a strict correlation and reciprocal regulation between PHOX2B and PHOX2B-AS1.

Simultaneously targeting Prrx2 and Hic1 in macrophages significantly alleviated SU5416/hypoxia-induced PH in rats. The differential roles of pulmonary resMФs and recMФs in pulmonary vascular remodeling highlight novel therapeutic targets for pulmonary arterial hypertension treatment, specifically through inhibition of Hic1 and Prrx2 in macrophages.

The results revealed the critical role of PRRX2+EC/SPP1+TAM cell communication in mediating gemcitabine resistance in PDAC. These findings provide new insights into potential therapeutic strategies, highlighting the importance of targeting the PRRX2+EC/SPP1+TAM axis and supporting the use of multidrug regimens to overcome resistance and improve patient outcomes in PDAC.

Furthermore, pharmacological inhibition of NRF2 signaling may overcome cisplatin resistance in high-risk patients with NFE2L2-mutant tumors. While the signature shows significant clinical potential, further independent validation is required before it can be adopted into routine clinical practice. We developed a robust nine-gene prognostic model for predicting Progression-Free Survival (PFS) in CC, which provides novel insights into HPV-associated oncogenesis and facilitates risk stratification and therapeutic decision-making in CC management.

This analysis established PRRX2-driven MMP2+myCAFs as pivotal mediators of CRC perineural invasion through TGF-β/ECM remodeling. The PRRX2 score serves as a biomarker for prognosis prediction and immunotherapy outcome.

Targeted mRNA sequencing can effectively detect fusion gene and has potential clinical application value in diagnosis and classificatation in hematologic diseases.

Additional replication experiments revealed that senescence inducers could partially counteract the impact of PRRX2 on pancreatic cancer. In conclusion, PRRX2 may serve as a potential therapeutic target for pancreatic cancer treatment.

The study showed that ATOX1, which is transcriptionally activated by PRRX2, contributes to HCC carcinogenesis by regulating cancer cell malignant behaviors, cuproptosis, and mitochondrial function. The PRRX2/ATOX1 axis could be a potential therapeutic target for HCC.

The ECM components were involved in various cell-cell interactions and correlated with tumor development and poor survival outcomes. The ECM prognostic model components could be potential targets for novel therapeutic interventions in colorectal cancer.

Cox proportional hazard regression analysis revealed that expression of Prx2 &lsqb;hazard ratio (HR), 2.551; 95% confidence interval (CI), 1.056-6.162; P=0.037], MVD (HR, 2.436; CI, 1.034-5.735; P=0.042) and FIGO stage (HR, 1.543; CI, 1.027-2.319; P=0.037) were independent factors for PFS time. In conclusion, the results of the present study suggested that Prx2 could act as a potential biomarker for predicting CSCC progression and prognosis and could be a novel target for antiangiogenic therapy of CSCC.

Although cell viability was reduced in both cell lines, only HB4a cells underwent apoptotic cell death, whereas other types of cellular death may be involved in MCF-7 cells. Taken together, these data provide insight into the anticancer mechanisms attributed to PLN effects, which acts as an inhibitor of DNA damage response (DDR) proteins and antioxidant enzymes.